Journey Medical Co. (NASDAQ:DERM) CEO Claude Maraoui Sells 18,147 Shares of Stock

Journey Medical Co. (NASDAQ:DERM) CEO Claude Maraoui sold 18,147 shares of the stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $5.13, for a total transaction of $93,094.11. Following the completion of the transaction, the chief executive officer now directly owns 2,092,874 shares of the company’s stock, valued at approximately $10,736,443.62. The trade was a 0.86 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Claude Maraoui also recently made the following trade(s):

• On Monday, March 3rd, Claude Maraoui sold 23,508 shares of Journey Medical stock. The shares were sold at an average price of $5.19, for a total transaction of $122,006.52.

Journey Medical Trading Up 3.2 %

NASDAQ:DERM opened at $5.23 on Thursday. The company’s 50 day moving average price is $4.54 and its 200-day moving average price is $5.07. Journey Medical Co. has a 52 week low of $2.85 and a 52 week high of $6.89. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 1.81. The stock has a market cap of $109.25 million, a price-to-earnings ratio of -5.56 and a beta of 0.96.

Institutional Investors Weigh In On Journey Medical

A number of institutional investors have recently made changes to their positions in the company. Tang Capital Management LLC purchased a new stake in shares of Journey Medical during the fourth quarter valued at approximately $6,747,000. Cetera Investment Advisers grew its position in Journey Medical by 21.8% in the 4th quarter. Cetera Investment Advisers now owns 13,839 shares of the company’s stock worth $54,000 after purchasing an additional 2,478 shares during the period. Citadel Advisors LLC bought a new stake in Journey Medical in the 4th quarter worth approximately $174,000. Kovitz Investment Group Partners LLC grew its position in Journey Medical by 112.9% in the 4th quarter. Kovitz Investment Group Partners LLC now owns 24,710 shares of the company’s stock worth $97,000 after purchasing an additional 13,105 shares during the period. Finally, Dimensional Fund Advisors LP bought a new stake in Journey Medical in the 4th quarter worth approximately $80,000. Hedge funds and other institutional investors own 7.25% of the company’s stock.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.